NCT01674621View on ClinicalTrials.gov

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

September 25, 2012

Primary Completion Date

August 2, 2013

Study Completion Date

August 2, 2013

Conditions
Post Menopausal Osteoporosis
Interventions
DRUG

Abaloparatide Transdermal (50 mcg)

Abaloparatide Transdermal Microneedle Active Patch

DRUG

Abaloparatide Transdermal (100 mcg)

Abaloparatide Transdermal Microneedle Active Patch

DRUG

Abaloparatide Transdermal (150 mcg)

Abaloparatide Transdermal Microneedle Active Patch

DRUG

Abaloparatide Injection (80 mcg)

Abaloparatide Subcutaneous Injection

DRUG

Abaloparatide Placebo

Abaloparatide Transdermal Microneedle Placebo Patch

Trial Locations (9)

20817

Bethesda

30319

Atlanta

80227

Lakewood

Unknown

Aalborg

Ballerup Municipality

Vejle

Tallinn

Lodz

Warsaw

Sponsors

Collaborators (1)

Nordic Bioscience A/S
All Listed Sponsors
collaborator

Nordic Bioscience A/S

INDUSTRY

lead

Radius Health, Inc.

INDUSTRY

NCT01674621 - Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis | Biotech Hunter | Biotech Hunter